934235-75-3

Upstream product

• 75-65-0 tert-butyl alcohol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 5692-26-2 (+/-)-N-(cyanophenylmethyl)benzamide 

Downstream Products

• 1026750-10-6 (2,4-diphenyl-oxazol-5-yl)-(pyridine-3-carbonyl)-carbamic acid tert-butyl ester 
• 1027842-27-8 (2,4-diphenyl-oxazol-5-yl)-(pyridine-4-carbonyl)-carbamic acid tert-butyl ester 
• 1026925-54-1 (2,4-diphenyl-oxazol-5-yl)-(2-propyl-pentanoyl)-carbamic acid tert-butyl ester 
• 1026938-72-6 (2,4-diphenyl-oxazol-5-yl)-(furan-2-carbonyl)-carbamic acid tert-butyl ester 
• 1028299-30-0 (2,4-diphenyl-oxazol-5-yl)-(thiophene-2-carbonyl)-carbamic acid tert-butyl ester 
• 1027322-96-8 (2,4-diphenyl-oxazol-5-yl)-(5-methyl-thiophene-2-carbonyl)-carbamic acid tert-butyl ester 
• 1026157-52-7 (benzofuran-2-carbonyl)-(2,4-diphenyl-oxazol-5-yl)-carbamic acid tert-butyl ester 
• 1026640-71-0 (benzo[b]thiophene-2-carbonyl)-(2,4-diphenyl-oxazol-5-yl)-carbamic acid tert-butyl ester 
• 1027322-56-0 (2,4-diphenyl-oxazol-5-yl)-(quinoline-2-carbonyl)-carbamic acid tert-butyl ester 
• 1026367-03-2 (benzothiazole-2-carbonyl)-(2,4-diphenyl-oxazol-5-yl)-carbamic acid tert-butyl ester 
• 1026403-00-8 (2,4-diphenyl-oxazol-5-yl)-(5-nitro-furan-2-carbonyl)-carbamic acid tert-butyl ester 
• 1026167-28-1 (2,4-diphenyl-oxazol-5-yl)-(4-fluoro-benzoyl)-carbamic acid tert-butyl ester 
• 1026044-08-5 (2,4-diphenyl-oxazol-5-yl)-(3-trifluoromethyl-benzoyl)-carbamic acid tert-butyl ester 
• 1025982-12-0 (2,4-diphenyl-oxazol-5-yl)-(4-trifluoromethyl-benzoyl)-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Development of a diversity-oriented approach to oxazole-5-amide libraries

(Chemical Equation Presented) A highly versatile route to oxazole-5-amides is presented. Conversion of readily accessible oxazole-5-trifluoroacetamides into their Boc-protected 5-aminooxazole derivatives provides intermediates amenable to parallel amide s

THIAZOLE AND OXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PRION DISEASES, CANCER AND CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AS WELL AS IN THE REGULATION OF STEM CELLS

Compounds of the formula (I) are provided: Fomula (I) wherein X, Y, R1, R2 and R3 are as defined in the specification. The compounds may be useful in the treatment of various diseases and conditions, in particular prion diseases.

Library synthesis and screening: 2,4-Diphenylthiazoles and 2,4-diphenyloxazoles as potential novel prion disease therapeutics

Transmissible spongiform encephalopathies (TSEs) are a family of invariably fatal neurodegenerative disorders for which no effective therapeutics are currently available. In this paper, we report on the synthesis and screening of a small library of 2,4-diphenylthiazol-5-ylamine and 2,4-diphenyloxazol-5- ylamine derivatives as potential novel prion disease therapeutics. Various synthetic strategies were investigated, including a novel phosgene-mediated cyclization of 2-N-benzoylphenylglycinonitrile, and a total of 45 compounds were synthesized. Library members were tested for both binding to prion protein (PrPC) using the surface plasmon resonance technique and for inhibition of PrPSc formation in persistently infected SMB cells. Of the compounds prepared, 15 were found to bind to human PrPC and six showed inhibition of PrPSc formation, displaying EC50s between 1.5 and 20 μM.